Respironics Acquires Japanese Supplier of Respiratory Products

Following the acquisition of a controlling interest in Fuju, RC Co. Ltd. (Tokyo, Japan), Respironics, Inc. (Pittsburgh, PA, USA) has agreed to purchase all outstanding shares of Fuji by December 31, 2006, for US$12 million. In addition, Respironics will assume about $11 million of Fuji's net indebtedness.

Fuji is a leading Japanese provider of hospital and homecare respiratory products. Historically, the company has focused on patients requiring ventilation assistance and, more recently, on the therapeutic and diagnostic needs of patients with obstructive sleep apnea (OSA). Over the past few years, the Japanese government has established reimbursement for both the diagnostic and therapeutic aspects of OSA. Fuji has annual revenues of around $32 million.

Respironics focuses on products and programs that manage sleep disordered breathing, chronic obstructive pulomonary disease (COPD), asthma, infant care, and restrictive lung disorders. "Respironics views Japan as one of the key emerging markets in sleep,” said James W. Liken, president and CEO of Respironics. "We look forward to serving this market with the combined resources of our two organizations.”





Related Links:
Respironics